1. Home
  2. STAI vs INTS Comparison

STAI vs INTS Comparison

Compare STAI & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STAI

ScanTech AI Systems Inc.

HOLD

Current Price

$0.23

Market Cap

24.6M

Sector

N/A

ML Signal

HOLD

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$0.43

Market Cap

24.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STAI
INTS
Founded
2011
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.6M
24.0M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
STAI
INTS
Price
$0.23
$0.43
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.33
AVG Volume (30 Days)
2.9M
3.3M
Earning Date
09-17-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,249,524.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
139.30
N/A
52 Week Low
$0.17
$0.19
52 Week High
$12.19
$3.17

Technical Indicators

Market Signals
Indicator
STAI
INTS
Relative Strength Index (RSI) 32.98 48.08
Support Level $0.26 $0.46
Resistance Level $0.30 $0.54
Average True Range (ATR) 0.05 0.06
MACD -0.01 0.00
Stochastic Oscillator 24.87 29.80

Price Performance

Historical Comparison
STAI
INTS

About STAI ScanTech AI Systems Inc.

ScanTech AI Systems Inc is developing and deploying security screening systems that protect travelers and other public members from criminals, terrorists, and other bad actors. It has developed a proprietary Computed Tomography scanning system that uses fixed-gantry technology to detect explosives, weapons, narcotics, and other contraband.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Share on Social Networks: